Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Melody Smith; Elena García-Martínez; Michael R. Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2018.1526250

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Melody Smith, Elena García-Martínez, Michael R. Pitter, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

171 Citations (Scopus)

Résumé

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

langue originale	Anglais
Numéro d'article	e1526250
journal	OncoImmunology
Volume	7
Numéro de publication	12
Les DOIs	https://doi.org/10.1080/2162402X.2018.1526250
état	Publié - 2 déc. 2018

Accès au document

10.1080/2162402X.2018.1526250

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{aca2008172ff4139842abfe16336de8e,

title = "Trial Watch: Toll-like receptor agonists in cancer immunotherapy",

abstract = "Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.",

keywords = "Ampligen{\textregistered}, Hiltonol{\textregistered}, SD-101, bacillus Calmette-Gu{\'e}rin, imiquimod, motolimod",

author = "Melody Smith and Elena Garc{\'i}a-Mart{\'i}nez and Pitter, {Michael R.} and Jitka Fucikova and Radek Spisek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/2162402X.2018.1526250",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

number = "12",

}

TY - JOUR

T1 - Trial Watch

T2 - Toll-like receptor agonists in cancer immunotherapy

AU - Smith, Melody

AU - García-Martínez, Elena

AU - Pitter, Michael R.

AU - Fucikova, Jitka

AU - Spisek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

AB - Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

KW - Ampligen®

KW - Hiltonol®

KW - SD-101

KW - bacillus Calmette-Guérin

KW - imiquimod

KW - motolimod

UR - http://www.scopus.com/inward/record.url?scp=85058033462&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1526250

DO - 10.1080/2162402X.2018.1526250

M3 - Review article

C2 - 30524908

AN - SCOPUS:85058033462

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 12

M1 - e1526250

ER -